553 related articles for article (PubMed ID: 26137404)
1. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J; Vacchelli E; Aranda F; Castoldi F; Eggermont A; Cremer I; Sautès-Fridman C; Fucikova J; Galon J; Spisek R; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2015 Apr; 4(4):e1008866. PubMed ID: 26137404
[TBL] [Abstract][Full Text] [Related]
2. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.
Garg AD; More S; Rufo N; Mece O; Sassano ML; Agostinis P; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2017; 6(12):e1386829. PubMed ID: 29209573
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial strategies for the induction of immunogenic cell death.
Bezu L; Gomes-de-Silva LC; Dewitte H; Breckpot K; Fucikova J; Spisek R; Galluzzi L; Kepp O; Kroemer G
Front Immunol; 2015; 6():187. PubMed ID: 25964783
[TBL] [Abstract][Full Text] [Related]
4. Trial watch: Chemotherapy with immunogenic cell death inducers.
Vacchelli E; Senovilla L; Eggermont A; Fridman WH; Galon J; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2013 Mar; 2(3):e23510. PubMed ID: 23687621
[TBL] [Abstract][Full Text] [Related]
5. Trial Watch: Chemotherapy with immunogenic cell death inducers.
Vacchelli E; Aranda F; Eggermont A; Galon J; Sautès-Fridman C; Cremer I; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014 Jan; 3(1):e27878. PubMed ID: 24800173
[TBL] [Abstract][Full Text] [Related]
6. Consensus guidelines for the detection of immunogenic cell death.
Kepp O; Senovilla L; Vitale I; Vacchelli E; Adjemian S; Agostinis P; Apetoh L; Aranda F; Barnaba V; Bloy N; Bracci L; Breckpot K; Brough D; Buqué A; Castro MG; Cirone M; Colombo MI; Cremer I; Demaria S; Dini L; Eliopoulos AG; Faggioni A; Formenti SC; Fučíková J; Gabriele L; Gaipl US; Galon J; Garg A; Ghiringhelli F; Giese NA; Guo ZS; Hemminki A; Herrmann M; Hodge JW; Holdenrieder S; Honeychurch J; Hu HM; Huang X; Illidge TM; Kono K; Korbelik M; Krysko DV; Loi S; Lowenstein PR; Lugli E; Ma Y; Madeo F; Manfredi AA; Martins I; Mavilio D; Menger L; Merendino N; Michaud M; Mignot G; Mossman KL; Multhoff G; Oehler R; Palombo F; Panaretakis T; Pol J; Proietti E; Ricci JE; Riganti C; Rovere-Querini P; Rubartelli A; Sistigu A; Smyth MJ; Sonnemann J; Spisek R; Stagg J; Sukkurwala AQ; Tartour E; Thorburn A; Thorne SH; Vandenabeele P; Velotti F; Workenhe ST; Yang H; Zong WX; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014 Oct; 3(9):e955691. PubMed ID: 25941621
[TBL] [Abstract][Full Text] [Related]
7. Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner.
Yang PM; Hsieh YY; Du JL; Yen SC; Hung CF
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326356
[TBL] [Abstract][Full Text] [Related]
8. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
Vacchelli E; Pol J; Bloy N; Eggermont A; Cremer I; Fridman WH; Galon J; Marabelle A; Kohrt H; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2015 Jan; 4(1):e985940. PubMed ID: 25949870
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
10. Chromomycin A
Florêncio KGD; Edson EA; Fernandes KSDS; Luiz JPM; Pinto FDCL; Pessoa ODL; Cunha FQ; Machado-Neto JA; Wilke DV
Front Immunol; 2022; 13():941757. PubMed ID: 36439184
[TBL] [Abstract][Full Text] [Related]
11. Anticancer metal drugs and immunogenic cell death.
Terenzi A; Pirker C; Keppler BK; Berger W
J Inorg Biochem; 2016 Dec; 165():71-79. PubMed ID: 27350082
[TBL] [Abstract][Full Text] [Related]
12. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Vanmeerbeek I; Sprooten J; De Ruysscher D; Tejpar S; Vandenberghe P; Fucikova J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L; Garg AD
Oncoimmunology; 2020; 9(1):1703449. PubMed ID: 32002302
[TBL] [Abstract][Full Text] [Related]
13. Trial watch: Chemotherapy with immunogenic cell death inducers.
Vacchelli E; Galluzzi L; Fridman WH; Galon J; Sautès-Fridman C; Tartour E; Kroemer G
Oncoimmunology; 2012 Mar; 1(2):179-188. PubMed ID: 22720239
[TBL] [Abstract][Full Text] [Related]
14. Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Sprooten J; Laureano RS; Vanmeerbeek I; Govaerts J; Naulaerts S; Borras DM; Kinget L; Fucíková J; Špíšek R; Jelínková LP; Kepp O; Kroemer G; Krysko DV; Coosemans A; Vaes RDW; De Ruysscher D; De Vleeschouwer S; Wauters E; Smits E; Tejpar S; Beuselinck B; Hatse S; Wildiers H; Clement PM; Vandenabeele P; Zitvogel L; Garg AD
Oncoimmunology; 2023; 12(1):2219591. PubMed ID: 37284695
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
16. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
Gazitt Y; Akay C; Thomas C
Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
[TBL] [Abstract][Full Text] [Related]
17. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
18. Trial watch: Naked and vectored DNA-based anticancer vaccines.
Bloy N; Buqué A; Aranda F; Castoldi F; Eggermont A; Cremer I; Sautès-Fridman C; Fucikova J; Galon J; Spisek R; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2015 May; 4(5):e1026531. PubMed ID: 26155408
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
20. Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma.
Boulin M; Guiu S; Chauffert B; Aho S; Cercueil JP; Ghiringhelli F; Krause D; Fagnoni P; Hillon P; Bedenne L; Guiu B
Anticancer Drugs; 2011 Sep; 22(8):741-8. PubMed ID: 21487286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
